[Form 4] Lyell Immunopharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Lyell Immunopharma director Sumant Ramachandra reported an equity award and updated holdings. He received an option grant covering 9,250 shares of common stock at an exercise price of $13.22 per share, expiring on June 9, 2036.

The option vests on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before it if his board service ends at that meeting) or the first anniversary of that date, contingent on continuous service. In addition, 10,000 shares of common stock are held indirectly by the Sumant Ramachandra Rev Trust DTD 01/24/12, where he is grantor and trustee. All share amounts reflect a 1-for-20 reverse stock split effected on May 30, 2025.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ramachandra Sumant

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	9,250	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Option (right to buy) — 9,250 shares (Direct, null); Common Stock — 10,000 shares (Indirect, Grantor and Trustee)

Footnotes (1)

1. On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split. Shares held by the Sumant Ramachandra Rev Trust DTD 01/24/12. The Reporting Person is grantor and trustee of the Sumant Ramachandra Rev Trust DTD 01/24/12. The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

Key Figures

Option grant size: 9,250 shares Option exercise price: $13.22 per share Option expiration: June 9, 2036 +3 more

6 metrics

Option grant size 9,250 shares Option (right to buy) common stock granted to director

Option exercise price $13.22 per share Strike price for 9,250-share option grant

Option expiration June 9, 2036 Expiration date of granted option

Indirect common shares 10,000 shares Common stock held by Sumant Ramachandra Rev Trust

Reverse stock split ratio 1-for-20 Reverse split of common stock on May 30, 2025

Net buy/sell direction neutral Transaction summary net buy/sell shares

Key Terms

1-for-20 reverse stock split, Grant, award, or other acquisition, Option (right to buy), Rev Trust, +1 more

5 terms

1-for-20 reverse stock split financial

"the Issuer effected a 1-for-20 reverse stock split of its common stock"

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Option (right to buy) financial

"security_title": "Option (right to buy)""

Rev Trust financial

"Shares held by the Sumant Ramachandra Rev Trust DTD 01/24/12"

continuous service financial

"subject to the Reporting Person providing continuous service through such date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ramachandra Sumant

(Last) (First) (Middle)

C/O LYELL IMMUNOPHARMA, INC.

201 HASKINS WAY, SUITE 101

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lyell Immunopharma, Inc. [ LYEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								10,000(1)	I	Grantor and Trustee(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$13.22	06/10/2026		A		9,250		(3)	06/09/2036	Common Stock	9,250	$0	9,250	D

Explanation of Responses:

1. On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split.

2. Shares held by the Sumant Ramachandra Rev Trust DTD 01/24/12. The Reporting Person is grantor and trustee of the Sumant Ramachandra Rev Trust DTD 01/24/12.

3. The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

	/s/ Mark Meltz, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Lyell Immunopharma (LYEL) report for Sumant Ramachandra?

Lyell Immunopharma reported an option grant to director Sumant Ramachandra for 9,250 shares of common stock and listed 10,000 shares held indirectly through his revocable trust, reflecting a routine equity compensation and updated ownership disclosure.

What are the key terms of Sumant Ramachandra’s new stock option at Lyell Immunopharma (LYEL)?

The option covers 9,250 shares of Lyell common stock at an exercise price of $13.22 per share, expiring June 9, 2036. Vesting depends on future service and the next annual stockholder meeting timing.

How and when will Sumant Ramachandra’s Lyell (LYEL) stock options vest?

The options vest on the earlier of the next annual stockholder meeting after June 10, 2026, or the first anniversary of June 10, 2026, provided he continues to serve the company through that vesting date.

How many Lyell Immunopharma (LYEL) shares does Sumant Ramachandra hold indirectly?

The filing shows 10,000 shares of Lyell common stock held indirectly by the Sumant Ramachandra Rev Trust DTD 01/24/12, for which he is both grantor and trustee, indicating beneficial ownership through that trust structure.

Did Lyell Immunopharma (LYEL) adjust reported share amounts for a reverse stock split?

Yes. The company effected a 1-for-20 reverse stock split of its common stock on May 30, 2025, and all share amounts in this insider report are stated on a post-split basis to reflect that corporate action.

What type of Form 4 transaction code applies to Sumant Ramachandra’s Lyell (LYEL) option grant?

The filing uses transaction code "A," which is described as a grant, award, or other acquisition. This indicates the option was awarded as compensation rather than purchased in an open-market transaction.